Migraine
Conditions
Keywords
Electroacupuncture therapy, Migraine, Acupuncture Therapy
Brief summary
A random controlled trail to evaluate the efficacy of migraine standard electroacupuncture formula, and to analysis the regulation of the intensity-effects and to observe the peripheral NO, CGRP and NF-кB expression level of migraine patients after electroacupuncture treatment.
Detailed description
acupuncture group(group A): treated by acupuncture for 20 days, 1 time per day control group(group B): treated by FlunarizineHydrochloride for 20 days, 1 table per day.
Interventions
DEVICEelectro-acupuncture
electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
flunarizine hydrochloride ，10mg/day，for 20 days。
Sponsors
Shanghai University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* met the diagnostic criteria for migraine; suffering from migraine attacks; migraine attacks for more than 5 days per month, and lasts for 3 months; voluntarily join this study with informed consents.
Exclusion criteria
* other systemic, neurological and psychiatric disorders; headache caused by other diseases; not treatment compliance during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Migraine Disability Assessment Questionnaire (MIDAS) | 20 days | a scientifically reliable and valid measure of migraine disability that can improve communication between patients and physicians, assess migraine severity and act as an outcome measure to monitor treatment efficacy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The medical outcomes study 36-item short-form health survey(SF-36) | 20 days | A 36-item short-form (SF-36) was constructed to survey health status in the Medical Outcomes Study |
| peripheral Nitrogen Monoxide(NO) protein expression | 20 days | marker |
| peripheral Calcitonin gene related peptide(CGRP) protein expression | 20 days | marker |
| peripheral Nuclear factor-kappa B(NF-кB) protein expression | 20 days | marker |
| Visual Analogue Scale (VAS) to assess pain | 20 days | Visual Analogue Scale (VAS) were applied to measure pain in patients |
Countries
China
Outcome results
None listed